1,158,094 Shares in Insmed, Inc. (NASDAQ:INSM) Acquired by Nuveen LLC

Key Points

• Nuveen LLC has acquired a significant stake in Insmed, purchasing approximately 1,158,094 shares valued at $88.35 million during the first quarter.
• Insider sales were reported, including a sale of 99,172 shares by S. Nicole Schaeffer at an average price of $93.42, reflecting a substantial decrease in their ownership.
• Insmed's quarterly earnings showed a loss of $1.70 per share, missing estimates, but revenues grew 18.9% year-over-year to $107.42 million.

Nuveen LLC purchased a new position in shares of Insmed, Inc. (NASDAQ:INSM - Free Report) in the 1st quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 1,158,094 shares of the biopharmaceutical company's stock, valued at approximately $88,351,000. Nuveen LLC owned 0.64% of Insmed as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. M&T Bank Corp boosted its stake in Insmed by 4.7% in the 1st quarter. M&T Bank Corp now owns 3,293 shares of the biopharmaceutical company's stock worth $252,000 after purchasing an additional 147 shares during the period. Snowden Capital Advisors LLC boosted its stake in Insmed by 2.5% in the 4th quarter. Snowden Capital Advisors LLC now owns 6,602 shares of the biopharmaceutical company's stock worth $456,000 after purchasing an additional 158 shares during the period. Cullen Frost Bankers Inc. boosted its stake in Insmed by 164.9% in the 1st quarter. Cullen Frost Bankers Inc. now owns 355 shares of the biopharmaceutical company's stock worth $27,000 after purchasing an additional 221 shares during the period. Nisa Investment Advisors LLC boosted its stake in Insmed by 6.5% in the 1st quarter. Nisa Investment Advisors LLC now owns 3,761 shares of the biopharmaceutical company's stock worth $287,000 after purchasing an additional 228 shares during the period. Finally, Parkman Healthcare Partners LLC boosted its stake in Insmed by 0.7% in the 4th quarter. Parkman Healthcare Partners LLC now owns 35,668 shares of the biopharmaceutical company's stock worth $2,463,000 after purchasing an additional 235 shares during the period.

Insmed Price Performance

Shares of NASDAQ INSM traded up $0.05 during trading hours on Friday, reaching $127.80. 3,528,446 shares of the stock traded hands, compared to its average volume of 2,934,935. The company has a market capitalization of $27.01 billion, a P/E ratio of -22.38 and a beta of 0.95. The company has a quick ratio of 6.33, a current ratio of 6.68 and a debt-to-equity ratio of 0.45. Insmed, Inc. has a 52-week low of $60.40 and a 52-week high of $128.48. The company's 50-day simple moving average is $103.62 and its two-hundred day simple moving average is $83.92.

Insmed (NASDAQ:INSM - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The biopharmaceutical company reported ($1.70) earnings per share for the quarter, missing analysts' consensus estimates of ($1.30) by ($0.40). The firm had revenue of $107.42 million for the quarter, compared to analysts' expectations of $104.06 million. Insmed had a negative net margin of 259.82% and a negative return on equity of 195.37%. The business's quarterly revenue was up 18.9% on a year-over-year basis. During the same period in the prior year, the business posted ($1.94) earnings per share. Equities research analysts forecast that Insmed, Inc. will post -4.56 EPS for the current year.

Insider Activity at Insmed

In related news, CEO William Lewis sold 129,805 shares of the firm's stock in a transaction that occurred on Monday, June 16th. The stock was sold at an average price of $100.39, for a total transaction of $13,031,123.95. Following the transaction, the chief executive officer directly owned 233,924 shares in the company, valued at $23,483,630.36. This trade represents a 35.69% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Orlov S. Nicole Schaeffer sold 99,172 shares of the firm's stock in a transaction that occurred on Wednesday, June 11th. The stock was sold at an average price of $93.42, for a total value of $9,264,648.24. Following the transaction, the insider owned 89,407 shares in the company, valued at approximately $8,352,401.94. The trade was a 52.59% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 525,716 shares of company stock valued at $49,665,671. Corporate insiders own 3.00% of the company's stock.

Analyst Upgrades and Downgrades

Several research analysts have commented on the company. Royal Bank Of Canada raised their target price on Insmed from $108.00 to $120.00 and gave the stock an "outperform" rating in a research note on Friday, August 8th. Morgan Stanley restated an "equal weight" rating and issued a $126.00 target price on shares of Insmed in a research note on Wednesday. The Goldman Sachs Group raised their target price on Insmed from $114.00 to $142.00 and gave the stock a "buy" rating in a research note on Wednesday. Citigroup raised Insmed to a "buy" rating in a report on Tuesday, June 10th. Finally, Bank of America raised their price target on Insmed from $94.00 to $109.00 and gave the company a "buy" rating in a report on Wednesday, June 11th. One equities research analyst has rated the stock with a hold rating and fifteen have issued a buy rating to the company's stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $129.57.

Insmed Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.